Bioclavis LTD

we're enabling the full promise and clinical utility of ‘omic testing to deliver cost-effective care for individual patients in coordination with and context of the practical realities in today’s healthcare systems. bioclavis leverages the proprietary tempo-seq® transcriptomic/genomic platform technology (developed by biospyder), capable of efficiently analyzing large cohorts with customizable biomarker panels of tens to thousands of genes, quickly and inexpensively. it has critical usability features, controls, and does not require specialized instrumentation, ideal for expansion into the clinic. these strengths--in concert with centralized patient samples, clinical research partners, and economic decision making--allow accelerating content discovery, product development and adoption of a new generation of cost-disruptive precision medicine testing worldwide.